Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 14/20 | 0.54 |
| ▸ | CDK2 | P24941 | 14/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.54 |
| ▸ | CDK4 | P11802 | 3/20 | 0.54 |
| ▸ | CCND1 | P24385 | 3/20 | 0.54 |
| ▸ | CDK9 | P50750 | 3/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.54 |
| ▸ | CDK11A | Q9UQ88 | 3/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195665 | 0.99 | CCNA2 (0.53) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6211465 | 0.94 | CCNA2 (0.56) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6192807 | 0.90 | CCNB2 (0.55) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6194606 | 0.90 | CCNT1 (0.53) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6194975 | 0.89 | CCNT1 (0.52) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6195125 | 0.89 | CCNT1 (0.52) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6194531 | 0.89 | CCNA2 (0.51) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6193477 | 0.89 | CCNA2 (0.52) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6194186 | 0.88 | CCNT1 (0.57) | CCNA2CDK2CCNT1CDK4CCND1 | |
| SCHEMBL6194698 | 0.88 | CCNT1 (0.51) | CCNA2CDK2CCNT1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | MKI67, TK1, CDK2 | CCNA2 138/4885CDK2 3/4885CCNT1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.